GSTM1 and Balkan nephropathy: An increased expression was documented in urine of patients with bladder cancer, prostate cancer, pancreatic cancer, colorectal cancer, breast cancer, lung cancer and solid sarcomas and proposed as a new theranostic marker [64,66,67,68] According to the results of multivariate regression analysis (Table 3), its plasma and urinary level were documented in significant interrelation with Hb level in BEN patients.